Selective express tumor diagnostic with narrow band nanophotonic structures (Q3128691)

From EU Knowledge Graph
Revision as of 12:18, 30 September 2021 by DG Regio (talk | contribs) (‎Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string)
Jump to navigation Jump to search
Project Q3128691 in Greece
Language Label Description Also known as
English
Selective express tumor diagnostic with narrow band nanophotonic structures
Project Q3128691 in Greece

    Statements

    0 references
    92,000.0 Euro
    0 references
    10 October 2017
    0 references
    9 October 2019
    0 references
    ΝΑΝΟΤΥΠΟΣ ΟΕ
    0 references
    0 references

    40°54'2.41"N, 22°57'19.80"E
    0 references

    35°11'2.58"N, 24°58'5.63"E
    0 references
    his EXODIAGNOS project proposal addresses the development of novel approach for tumor diagnostics. A new selective, early-stage, non-invasive, express cancer diagnostic procedure utilizing exosomal vesiclesand their content recognition by specially designed narrow bandwidth active/passive nano- andmicrophotonic sensors will be proposed for clinical trials.Our approach is based on three recently suggested novelties.(i) Recognition of exosomal biomarkers – surface and intravesicular proteins and mRNA and DNA nucleic acids – as tumor markers.(ii) Amplitude and phase detection methods using narrow band localized plasmonic resonances and resonances in microcavities, to make a breakthrough in the sensitivity and selectivity of the respective bioand environmental sensors.(iii) Ultra-sensitive detection promised by Active Plasmonic Platform (quantum emitters coupled with the plasmonic nanoresonators and/or microresonators). (Greek)
    0 references
    his EXODIAGNOS project proposal addresses the development of novel approach for tumor diagnostics. A new selective, early-stage, non-invasive, express cancer diagnostic procedure utilising exosomal vesiclesand their content recognition by specially designed narrow bandwidth active/passive nano- andmicrophotonic sensors will be proposed for clinical trials.Our approach is based on three recently suggested Novelties.(i) Recognition of exosomal biomarkers surface and intravesicular proteins and mRNA and DNA nucleic acids as tumor markers.(ii) amplitude and phase detection methods using narrow band localised plasmonic resonances and resonances in microcavities, to make a breakthrough in the sensitivity and selectivity of the respective bioand environmental sensors.(iii) Ultra-sensitive detection promised by Active plasmonic Platform (quantum emitters coupled with the plasmonic nanoresonators and/or microresonators). (English)
    30 September 2021
    0 references

    Identifiers

    5.017.617
    0 references